New developments in Cryptosporidium research by Ryan, U. & Hijjawi, N.
  
MURDOCH RESEARCH REPOSITORY 
 
 
 
 
This is the author’s final version of the work, as accepted for publication  
following peer review but without the publisher’s layout or pagination.  
The definitive version is available at 
http://dx.doi.org/10.1016/j.ijpara.2015.01.009 
 
 
 
 
 
Ryan, U. and Hijjawi, N. (2015) New developments in 
Cryptosporidium research. International Journal for 
Parasitology, 45 (6). pp. 367-373. 
 
 
 
http://researchrepository.murdoch.edu.au/26044/ 
 
 
 
 
 
 
Crown copyright © 2015 Australian Society for Parasitology Inc. 
 
It is posted here for your personal use. No further distribution is permitted. 
 
 
Accepted Manuscript
Invited review
New developments in Cryptosporidium research
Una Ryan, Nawal Hijjawi
PII: S0020-7519(15)00047-8
DOI: http://dx.doi.org/10.1016/j.ijpara.2015.01.009
Reference: PARA 3745
To appear in: International Journal for Parasitology
Received Date: 30 October 2014
Revised Date: 20 January 2015
Accepted Date: 21 January 2015
Please cite this article as: Ryan, U., Hijjawi, N., New developments in Cryptosporidium research, International
Journal for Parasitology (2015), doi: http://dx.doi.org/10.1016/j.ijpara.2015.01.009
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting proof before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  
1 
Invited Review 1 
 2 
New developments in Cryptosporidium research 3 
 4 
Una Ryana*1, Nawal Hijjawib 5 
 
6 
aSchool of Veterinary and Life Sciences, Vector- and Water-Borne Pathogen Research Group, 7 
Murdoch University, Murdoch, Western Australia 6150, Australia  8 
bDepartment of Medical Laboratory Sciences, Faculty of Allied Health Sciences, The Hashemite 9 
University PO Box 150459, Zarqa, 13115, Jordan 10 
 11 
 12 
 13 
*Corresponding author. Tel.: +61 8 93602482. 14 
E-mail address: Una.Ryan@murdoch.edu.au (U. Ryan) 15 
1Australian Society for Parasitology 2014 Bancroft-Mackerras Medal Oration. 16 
 17 
  18 
  
2 
Abstract 19 
 Cryptosporidium is an enteric parasite that is considered the second greatest cause of 20 
diarrhoea and death in children after rotavirus. Currently, 27 species are recognized as valid and of 21 
these, Cryptosporidium hominis and Cryptosporidium parvum are responsible for the majority of 22 
infections in humans. Molecular and biological studies indicate that Cryptosporidium is more 23 
closely related to gregarine parasites rather than to coccidians. The identification of gregarine-like 24 
gamont stages and the ability of Cryptosporidium to complete its life cycle in the absence of host 25 
cells further confirm its relationship with gregarines. This opens new avenues into the investigation 26 
of pathogenesis, epidemiology, treatment and control of Cryptosporidium. Effective drug treatments 27 
and vaccines are not yet available due, in part, to the technical challenges of working on 28 
Cryptosporidium in the laboratory. Whole genome sequencing and metabolomics have expanded 29 
our understanding of the biochemical requirements of this organism and have identified new drug 30 
targets. To effectively combat this important pathogen, increased funding is essential. 31 
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1. Introduction 37 
 Cryptosporidium is an enteric protozoan parasite of medical and veterinary importance that 38 
infects a wide range of humans and animals worldwide. A recent epidemiological study 39 
investigating the cause and effect of diarrhoea in over 22,000 children (under 5 years of age), 40 
residing in four African and three Asian study sites, identified cryptosporidiosis as the second most 41 
common pathogen responsible for severe diarrhoea and was also associated with death in young 42 
children (12 - 23 months of age) (Kotloff et al., 2013). Globally, cryptosporidiosis is estimated to be 43 
responsible for 30 - 50% of the deaths in children under 5 years of age and is considered the second 44 
greatest cause of diarrhoea and death in children after rotavirus (Ochoa et al., 2004; Snelling et al., 45 
2007; Striepen, 2013). Infection in this age group is also associated with developmental problems 46 
(Guerrant et al., 1999).  47 
 Cryptosporidiosis commonly results in watery diarrhea that may sometimes be profuse and 48 
prolonged (Current and Garcia, 1991; Chalmers and Davies, 2010; Bouzid et al., 2013). Other 49 
common symptoms include abdominal pain, nausea, vomiting and low-grade fever. Occasionally, 50 
non-specific symptoms such as myalgia, weakness, malaise, headache and anorexia occur (Current 51 
and Garcia, 1991). Immunocompetent individuals experience a transient self-limiting illness (up to 52 
2 to 3 weeks). However, for immunocompromised patients such as HIV-infected individuals, 53 
symptoms may include chronic or protracted diarrhea and prior to the use of antiretroviral therapy 54 
cryptosporidiosis was associated with significant mortality (Manabe et al., 1998; Hunter and 55 
Nichols, 2002). Infections among HIV-infected individuals may also become extra-intestinal, 56 
spreading to other sites including the gall bladder, biliary tract, pancreas and pulmonary system 57 
(López-Vélez et al., 1995; Hunter and Nichols, 2002). Transmission of the parasite occurs via the 58 
fecal-oral route, either by ingestion of contaminated water or food, or by person-to-person or 59 
animal-to-human transmission (Xiao, 2010). Waterborne transmission is considered a major mode 60 
of transmission and Cryptosporidium was the etiological agent in 60.3% (120) of the waterborne 61 
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protozoan parasitic outbreaks that have been reported worldwide between 2004 and 2010 62 
(Baldursson and Karanis, 2011).   63 
  Current treatment options for cryptosporidiosis are limited and only one drug, nitazoxanide 64 
(NTZ), has been approved by the United States (US) Food and Drug Administration (FDA). This 65 
drug, however, exhibits only moderate clinical efficacy in children and immunocompetent people, 66 
and none in people with HIV (Abubakar et al., 2007; Amadi et al., 2009).  67 
 68 
2. Taxonomy 69 
Cryptosporidium is an apicomplexan parasite and, until recently, belonged to the order 70 
Eucoccidiorida (which includes Toxoplasma, Cyclospora, Isospora and Sarcocystis) (Levine, 1984). 71 
Genomic and biochemical data indicate that Cryptosporidium differs from other apicomplexans in 72 
that it has lost the apicoplast organelle, as well as genomes for both the plastid and the 73 
mitochondrion (Zhu et al., 2000; Abrahamsen et al., 2004; Xu et al., 2004). Cryptosporidium also 74 
demonstrates several peculiarities that separate it from any other coccidian. These include (i) the 75 
location of Cryptosporidium within the host cell, where the endogenous developmental stages are 76 
confined to the apical surfaces of the host cell (intracellular, but extracytoplasmic); (ii) the 77 
attachment of the parasite to the host cell, where a multi-membranous attachment or feeder 78 
organelle is formed at the base of the parasitophorous vacuole (PV) to facilitate the uptake of 79 
nutrients from the host cell; (iii) the presence of two morpho-functional types of oocysts, thick-80 
walled and thin-walled, with the latter responsible for the initiation of the auto-infective cycle in the 81 
infected host; (iv) the small size of the oocyst (5.0 x 4.5 µm for Cryptosporidium parvum) which 82 
lacks morphological structures such as sporocyst, micropyle and polar granules (Tzipori and 83 
Widmer, 2000; Petry, 2004); (v) the insensitivity to all anti-coccidial agents tested to date 84 
(Blagburn and Soave, 1997; Cabada and White, 2010); (vi) cross-reaction of an anti-cryptosporidial 85 
monoclonal antibody with gregarines (Bull et al., 1998), and (vii) the observation of the presence of 86 
novel gamont-like extracellular stages similar to those found in gregarine life cycles (Hijjawi et al., 87 
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2002; Rosales et al., 2005; Karanis et al., 2008; Borowski et al., 2010; Koh et al., 2013, 2014; 88 
Huang et al., 2014).  89 
Molecular studies indicate that Cryptosporidium is more closely related to the primitive 90 
apicomplexan gregarine parasites rather than to coccidians (Carreno et al., 1999; Leander et al., 91 
2003). Recent whole genome analysis comparing Cryptosporidium with the 92 
gregarine Ascogregarina taiwanensis supports this phylogenetic association (Templeton et al., 93 
2010). Ascogregarina and Cryptosporidium, however, also possess features that unite them with the 94 
Coccidia, including an environmental oocyst stage, metabolic pathways such as the Type I fatty 95 
acid and polyketide synthetic enzymes, and a number of conserved extracellular protein domain 96 
architectures (Templeton et al., 2010). Future genomic studies of other gregarine parasites will 97 
hopefully provide a clearer understanding of the correct taxonomic placement of the genus 98 
Cryptosporidium. Further characterization of these novel gamont-like developmental stages, which 99 
are similar to those of gregarines, will also contribute to a greater understanding of the 100 
environmental ecology of Cryptosporidium, which is fundamental to its control (Barta and 101 
Thompson, 2006). A better understanding of the relationship between Cryptosporidium and 102 
gregarines will also open up new approaches into the investigation of pathogenesis, epidemiology, 103 
treatment and control of Cryptosporidium. 104 
Delimiting species within the genus Cryptosporidium has also been controversial but 105 
currently 27 species are regarded as valid (Ryan et al., 2014, 2015). Three of these are avian 106 
Cryptosporidium spp.; Cryptosporidium meleagridis, Cryptosporidium baileyi and 107 
Cryptosporidium galli, 19 are species in mammals; Cryptosporidium muris, C. parvum, 108 
Cryptosporidium wrairi, Cryptosporidium felis, Cryptosporidium andersoni, Cryptosporidium canis, 109 
Cryptosporidium hominis, Cryptosporidium suis, Cryptosporidium bovis, Cryptosporidium fayeri, 110 
Cryptosporidium macropodum, Cryptosporidium ryanae, Cryptosporidium xiaoi, Cryptosporidium 111 
ubiquitum, Cryptosporidium cuniculus, Cryptosporidium tyzzeri, Cryptosporidium viatorum, 112 
Cryptosporidium scrofarum and Cryptosporidium erinacei;  one  (Cryptosporidium fragile) is a 113 
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species in amphibians; two (Cryptosporidium serpentis and Cryptosporidium varanii) are species in 114 
reptiles; and two (Cryptosporidium molnari and Cryptosporidium huwi) are species in fish (Ryan 115 
and Xiao, 2014; Ryan et al., 2014, 2015). There are also over 40 genotypes, with a high probability 116 
that many of these will eventually be given species status with increased biological and molecular 117 
characterisation.  118 
In humans, nearly 20 Cryptosporidium spp. and genotypes have been reported, including C. 119 
hominis, C. parvum, C. meleagridis, C. felis, C. canis, C. cuniculus, C. ubiquitum, C. viatorum, C. 120 
muris, C. suis, C. fayeri, C. andersoni, C. bovis, C. scrofarum, C. tyzzeri, C. erinacei and 121 
Cryptosporidium horse, skunk and chipmunk I genotypes, with C. hominis and C. parvum most 122 
commonly reported (Xiao, 2010; Ryan et al., 2014). Other species,such as C. meleagridis, C. felis, 123 
C. canis, C. cuniculus, C. ubiquitum and C. viatorum are less common. The remaining 124 
Cryptosporidium spp. and genotypes have been found in only a few human cases (Xiao, 2010; Ryan 125 
et al., 2014). These Cryptosporidium spp. infect both immunocompetent and immunocompromised 126 
persons.   127 
Molecular analysis using highly variable loci such as the 60 kDa glycoprotein (gp60) has 128 
revealed that C. hominis appears to be highly human-specific. Whilst some C. parvum subtypes 129 
such as the IIc subtype family are transmitted anthroponotically, other C. parvum subtypes are 130 
transmitted zoonotically (Xiao, 2010; Ryan et al., 2014).  131 
 132 
3. Life cycle and cell culture 133 
 Cryptosporidium has a complex, monoxenous life cycle consisting of several developmental 134 
stages involving both sexual and asexual cycles (Fig. 1). The infective sporulated oocyst is excreted 135 
from the body of an infected host in the faeces. The oocysts possess a tough trilaminar wall, which 136 
is extremely resistant to chemical and mechanical disruption, and maintains the viability of the 137 
internal sporozoites under adverse environmental conditions (Fayer and Unger, 1986). This wall is 138 
  
7 
very rigid (Chatterjee et al., 2010) and atomic force microscopy shows that the oocyst wall 139 
resembles common plastic materials (Dumètre et al., 2013). 140 
 Once ingested, oocysts release sporozoites in the intestine, where infections are 141 
predominately localized to the jejunum and ileum. Cell invasion by the sporozoite is followed by 142 
intracellular development to a trophozoite stage which undergos asexual proliferation to produce 143 
two different types of meronts. Merozoites released from type I meronts enter other intestinal 144 
epithelial cells and either develop into type II meronts or complete another cycle of type I meronts. 145 
Merozoites from type II meronts then multiply sexually to produce microgamonts and 146 
macrogamonts. The microgamonts fertilize the macrogamonts producing zygotes, which mature 147 
into oocysts (Hijjawi, 2010).  148 
 The presence of gamont-like extracellular stages in the life cycle of Cryptosporidium was 149 
first observed in a study by Hijjawi et al. (2002) and has since been reported by several 150 
investigators (Rosales et al., 2005; Karanis et al., 2008; Borowski et al., 2010; Koh et al., 2013, 151 
2014; Huang et al., 2014). The origin of the extracellular stages is not known but it has been 152 
suggested that these stages might originate from sporozoites which failed to penetrate the host cells 153 
and developed extracellularly into motile trophozoite stages (Hijjawi et al., 2004; Rosales et al., 154 
2005). Extracellular gamont-like stages have also been purified from mice infected with C. parvum 155 
(Hijjawi et al., 2004). 156 
A major hurdle for research laboratories to facilitate biological, pathological, immunological 157 
and molecular and drug evaluation studies on Cryptosporidium has been the inability to 158 
continuously propagate Cryptosporidium in vitro. In addition, there are no methods allowing the 159 
indefinite storage of infectious material and isolates have to be continuously passaged through 160 
animals, usually calves or mice for C. parvum and piglets and gerbils for C. hominis (Tzipori and 161 
Widmer, 2008). 162 
Factors that affect the development and proliferation of Cryptosporidium in in vitro culture 163 
include the excystation protocol, age and strain of the parasite, stage and size of inoculum, host cell 164 
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type, maturity and culture conditions such as pH, medium supplements and atmosphere (Hijjawi, 165 
2010; Karanis and Aldeyarbi, 2011). The majority of in vitro cultivation studies to date use human 166 
adenocarcinoma (HCT-8) cells, as this cell line supports superior development of the parasite in a 167 
conventional 5% CO2 environment compared with other cell lines and atmospheres but still suffers 168 
from failure to propagate the parasite long-term, low yields of oocysts and/or lack of reproducibility 169 
(Hijjawi, 2010; Karanis and Aldeyarbi, 2011). Long-term culturing (up to 25 days) of 170 
Cryptosporidium in cell culture using pH modification, sub-culturing and gamma irradiation has 171 
been reported (Hijjawi et al., 2001). Reducing the volume of excystation medium and centrifugation 172 
of excysting oocysts onto the cell monolayer has also reportedly resulted in an approximately four-173 
fold increase in sporozoite attachment and subsequent infection (King et al., 2011). Another study 174 
cultivated intact crypts from human intestinal fragments of intestinal layers with culture medium 175 
supplemented with growth factors and antiapoptotic molecules but only reported that 176 
Cryptosporidium development increased for >120 h (Castellanos-Gonzalez et al., 2013). 177 
Nonetheless, high throughput screening of Cryptosporidium, using HCT-8 cultures, for viability 178 
and drug analysis has been achieved (King et al., 2011; Bessoff et al., 2013; Jefferies et al., 2015). 179 
Complete development of Cryptosporidium in a cell-free (axenic) in vitro cultivation system 180 
was first reported by Hijjawi et al. (2004). According to this report, new oocysts were present after 181 
8 days post-culture inoculation (Hijjawi et al., 2004). Other researchers such as Girouard et al. 182 
(2006), who used similar but not identical serum-free cultivation systems, were unable to reproduce 183 
these results. However, multiplication of Cryptosporidium DNA from cell-free cultures has been 184 
reported by other researchers (Zhang et al., 2009; Hijjawi et al., 2010; Koh et al., 2013) and various 185 
Cryptosporidium developmental stages (sporozoites, trophozoites, large meronts, merozoites, 186 
microgamonts, gamont-like cells and extra-large gamont-like cells) have been identified from 187 
biofilms using various techniques including scanning electron microscopy (SEM) (Koh et al., 2013, 188 
2014). A previous study had suggested that the presence of gamont-like stages in both cell-free and 189 
in-vitro cultures was due to contaminating debris or fungal infection resembling Bipolaris 190 
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australiensis and Colletotrichum acutatum (Woods and Upton, 2007). In the most recent study by 191 
Koh et al. (2014), however, intense immunofluorescent labelling of the internal structures of 192 
gamont-like stages using a Cryptosporidium-specific antibody counters this argument. The authors 193 
suggested that the role of the gamont-like stage is to generate trophozoites and merozoites so that 194 
more new oocysts can be produced without host encapsulation (Koh et al., 2014). The latter study 195 
also demonstrated that Cryptosporidium has the ability to form a PV independent of a host (in both 196 
biofilms and HCT-8 cell cultures) (Koh et al., 2014), which is consistent with the proposal by 197 
Pohlenz et al. (1978) that Cryptosporidium does not require host encapsulation to form a PV.  198 
Another study identified sporozoites, trophozoites and type I merozoites in cell-free cultures 199 
by SEM and compared gene expression in cell culture and cell-free culture (Yang et al., 2015). 200 
Findings from that study showed that gene expression patterns in cell culture and cell-free culture 201 
were similar but in cell-free culture, gene expression was delayed in some genes and was lower 202 
(Yang et al., 2015). A recent study conducted a genome-wide transcriptome analysis over a 72 h in 203 
vitro culture of C. parvum-infected HCT-8 cells (Mauzy et al., 2012). Quantitative-PCR (qPCR) for 204 
3,302 genes (87% of the protein coding genes) indicated that each gene has detectable transcription 205 
in at least one time point assessed (Mauzy et al., 2012). Further studies which involve a wider range 206 
of genes should be conducted to better understand the expression of Cryptosporidium genes in cell-207 
free culture. 208 
Numerous studies have reported aggregations of trophozoites in cell-free culture (Hijjawi et 209 
al., 2004, 2010; Boxell et al., 2008; Koh et al., 2014; Yang et al., 2015) and it has been suggested 210 
that trophozoites may have fused together by a syzygy-like process (Hijjawi et al., 2004). More 211 
recently, all life cycle stages from cell-free culture have been described using electron microscopy 212 
(Aldeyarbi and Karanis, 2014, unpublished data). The authors also reported different 213 
Cryptosporidium stages developing within the shells of the oocysts, the detection of gregarine-like 214 
stages and syzygy and a PV (Aldeyarbi and Karanis, 2014, unpublished data). A cell-free in vitro 215 
cultivation system for Cryptosporidium represents a significant advance that will be extremely 216 
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useful in drug assessment and in research on developmental biology, avoiding the need for 217 
infectivity experiments with animal models or cell culture (Karanis and Aldeyarbi, 2011). It is 218 
hoped that with further advances in cell-free culturing, more researchers skilled in immunology, 219 
biochemistry and molecular biology will apply these skills to Cryptosporidium. 220 
  221 
4. Vaccines 222 
The immune status of the host plays a critical role in determining susceptibility to infection 223 
with this parasite as well as the outcome and severity of cryptosporidiosis. Therefore understanding 224 
host-parasite interactions and the essential elements of immunity to Cryptosporidium spp. are 225 
essential to the development of effective immunotherapies or vaccines (Mead, 2014). A complex 226 
sequence of events involving various components of the innate and adaptive host response has been 227 
shown to be important in the control of Cryptosporidium infection (Petry et al., 2010; McDonald et 228 
al., 2013). Yet the nature of these responses, particularly in humans, is not completely understood 229 
(Borad and Ward, 2010). However, as this parasite is largely localised to the intestinal tract, a 230 
vaccine that stimulates mucosal immune responses will likely be most beneficial (Mead, 2014). For 231 
example, commercially available mucosal vaccines against other enteric pathogens such as 232 
rotavirus, that are live and attenuated, have achieved considerable success in disease prevention and 233 
control in children in developed countries (Pasetti et al., 2011), but lower protection in children in 234 
developing countries (Vesikari, 2012). The use of an attenuated Cryptosporidium strain could 235 
therefore result in better immunological responses and protection from symptomatic disease and/or 236 
infection. Several lines of evidence support this. For example, dairy calves inoculated with gamma-237 
irradiated C. parvum oocysts were protected against subsequent challenge (Jenkins et al., 2004). In 238 
pigs, C. hominis-specific immunity was sufficient to completely protect against challenge with the 239 
same species (Sheoran et al., 2012). In a second group of pigs, primary infection with C. hominis 240 
and subsequent infection with C. parvum resulted in a partial cross-protective immunity with milder 241 
symptoms and lower oocyst shedding than C. parvum only infected controls (Sheoran et al., 2012). 242 
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Studies in human volunteers have shown that re-challenge with the same C. parvum isolate, 1 year 243 
after recovery from cryptosporidiosis, did not prevent infection but did reduce its severity 244 
(Okhuysen et al., 1998). Indeed, it has been suggested that regular exposure to low doses of 245 
Cryptosporidium are beneficial, as Cryptosporidium infection rates were significantly higher for 246 
outbreaks associated with groundwater than surface water consumption (Craun et al., 1998; Hunter 247 
and Quigley, 1998). The authors argued that people who use surface water sources were regularly 248 
exposed to small numbers of oocysts and thus did not experience many outbreaks, unless there was 249 
a major breakdown in treatment (Craun et al., 1998; Hunter and Quigley, 1998). Development of 250 
vaccines containing Cryptosporidium parasites that have been rendered incapable of causing disease, 251 
through irradiation or genetic engineering, and identification of effective cryopreservation methods 252 
is likely the best approach for the development of potential vaccine strains (Striepen, 2012; Mead, 253 
2014). However, it is important to remember that malnutrition and the associated reduction in 254 
immunity (Coutinho et al., 2008) may lower the effectiveness of any Cryptosporidium vaccine used 255 
on children in developing countries. This is particularly sobering in light of that fact that there are 256 
currently >842 million chronically malnourished persons worldwide 257 
(http://www.fao.org/docrep/018/i3458e/i3458e.pdf).  258 
 259 
5. Genomics 260 
The sequencing of the genomes of C. parvum, C. hominis and C. muris has been a major 261 
advance in our understanding of the molecular biology of Cryptosporidium (Abrahamsen et al., 262 
2004; Xu et al., 2004; Widmer and Sullivan, 2012; Widmer et al., 2012). The genomes of C. 263 
parvum and C. hominis display 95 - 97% DNA sequence identity and ~30% GC content, with no 264 
large indels or rearrangements evident (Widmer and Sullivan, 2012). They are each 9.2 million 265 
bases (Mb) in size and encode 4000 genes (Abrahamsen et al., 2004; Xu et al., 2004). The genome 266 
of C. parvum is essentially fully assembled (13 scaffolds representing eight chromosomes; see 267 
www.cryptodb.org), whereas the C. hominis genome still has some gaps (90 scaffolds; see 268 
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www.cryptodb.org). Approximately 75.3% of the C. parvum genome is annotated as coding 269 
(Abrahamsen et al., 2004). Cryptosporidium (together with gregarines) has lost its apicoplast, and C. 270 
parvum and C. hominis have a degenerate ‘mitosome’ instead of a mitochondrion, and have lost the 271 
mitochondrial genome and nuclear genes for many mitochondrial proteins, including those required 272 
for the tricarboxylic acid (TCA) cycle, oxidative phosphorylation, and fatty acid oxidation 273 
(Abrahamsen et al., 2004; Xu et al., 2004; Templeton et al., 2010). Also absent are genes for de 274 
novo biosynthesis of amino acids, nucleotides and sugars, as well as mechanisms for splicing RNA 275 
and gene silencing (Abrahamsen et al., 2004; Xu et al., 2004). Loss of genes from multiple 276 
metabolic pathways means C. parvum and C. hominis rely heavily on scavenging nutrients from the 277 
host, salvage rather than de novo biosynthesis, and glycolysis or substrate-level phosphorylation for 278 
energy production. 279 
A recent comparison of the genome of the anthroponotic C. parvum isolate TU114 (gp60 280 
IIc) and the reference genome originating from the zoonotic C. parvum isolate IOWA identified a 281 
small number of highly diverged genes (Widmer et al., 2012). Among these, transporters were 282 
significantly over-represented, which suggests that the ability to establish an infection in a 283 
particular host species may depend in part on transporters controlling the exchange of metabolites 284 
between the host cell and intracellular developmental stages of the parasite (Widmer et al., 2012). 285 
Further genome sequencing is required to confirm this. Interestingly, a three-way comparison of the 286 
newly sequenced anthroponotic C. parvum TU114 isolate, the reference zoonotic C. parvum 287 
(IOWA) and C. hominis identified at least three genes where the anthroponotic C. parvum sequence 288 
was more similar to C. hominis than to the zoonotic C. parvum reference. Because C. hominis and C. 289 
parvum IIc are human parasites, this raises the possibility that their evolution is driven by the 290 
adaptation of the parasite to different host species (Widmer et al., 2012). 291 
 A draft de novo assembly of the C. muris genome has been available from online public 292 
databases (e.g., CryptoDB, cryptodb.org) since 2008 (Widmer and Sullivan, 2012). The C. muris 293 
genome overall is similar in size, nucleotide composition and gene content to the other two species, 294 
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with a few notable exceptions, e.g., the nuclear genome encodes a complete set of TCA cycle 295 
enzymes, genes required for oxidative phosphorylation, and a functional ATP synthase (Mogi and 296 
Kita, 2010). Similar to C. parvum and C. hominis, C. muris lacks a cytochrome-based respiratory 297 
chain and shows no evidence of having a mitochondrial genome (Widmer and Sullivan, 2012). 298 
However, the presence of mitochondrial structure and proteins that are absent from C. parvum and 299 
C. hominis, but present in C. muris and gregarines (Uni et al., 1987; Toso and Omoto, 2007; Mogi 300 
and Kita, 2010), supports the theory that the common ancestor of gregarines and Cryptosporidium 301 
had a larger complement of mitochondrial proteins than C. parvum and C. hominis, and that the loss 302 
of mitochondria in C. parvum and C. hominis occurred after they diverged from C. muris (Widmer 303 
and Sullivan, 2012).  304 
 Functional genomics in Cryptosporidium has been hampered by the lack of a transfection 305 
system due to the complex life cycle of the parasite and a lack of effective endogenous promoters. 306 
A transient expression system using GFP, has been developed based on the double-stranded RNA 307 
(dsRNA) C. parvum virus (CPV) harboured by Cryptosporidium (Li et al., 2009). More recently, a 308 
DNA-based transient transfection of yellow (YFP) or red (RFP) fluorescent protein in C. parvum 309 
oocysts and sporozoites controlled by the endogenous promoters of actin, alpha tubulin and myosin 310 
genes using the restricted enzyme-mediated integration technique has been described (Li et al., 311 
2014). Further research is required to develop a stable transfection system, which will be helpful in 312 
determining the function and localization of novel Cryptosporidium proteins.  313 
 314 
6. Drug discovery 315 
 Progress in developing anti-cryptosporidial drugs has also been slow due to the limitations 316 
of in vitro culture for Cryptosporidium, an inability to genetically manipulate the organism and the 317 
unique metabolic features in this parasite, which has a highly streamlined metabolism and is unable 318 
to synthesize nutrients de novo (Abrahamsen et al., 2004; Andrews et al., 2014; Guo et al., 2014). 319 
As discussed, Cryptosporidium has completely lost the plastid-derived apicoplast present in many 320 
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other apicomplexans, and the remnant mitochondrion lacks the citrate cycle and cytochrome-based 321 
respiratory chain. Therefore, many classic drug targets are unavailable in Cryptosporidium and 322 
novel targets need to be identified for drug development (Guo et al., 2014). However, essential core 323 
metabolic pathways, including energy metabolism and lipid synthesis, are present in this parasite. 324 
Many enzymes within these pathways may serve as new drug targets because they are either absent 325 
in, or highly divergent from, humans and animals. For example, the C. parvum genome encodes 326 
three long chain fatty acyl-coenzyme A synthetases (LC-ACS) which are essential in fatty acid 327 
metabolism (Abrahamsen et al., 2004). A recent study reported good efficacy of the ACS inhibitor 328 
triacsin C against cryptosporidial infection in mice (Guo et al., 2014).  329 
 Another enzyme pathway that has been extensively examined is the salvage of adenosine 330 
from its host or environment as Cryptosporidium is unable to synthesize purine nucleotides de novo 331 
(Striepen et al., 2004; Umejiego et al., 2004; Kirubakaran et al., 2012). Cryptosporidium does not 332 
contain guanine salvage enzymes and consequently this pathway appears to be the only route to 333 
source guanine nucleotides (Striepen et al., 2004; Kirubakaran et al., 2012). The inosine 5’ - 334 
monophosphate dehydrogenase (IMPDH) gene in Cryptosporidium appears to have been acquired 335 
through lateral gene transfer from an ε-proteobacterium (Striepen et al., 2002, 2004) and recent 336 
studies have shown that compounds optimised for inhibition of cryptosporidial IMPDH also have 337 
antibacterial activity (Mandapati et al., 2014). Detailed kinetic analysis of this prokaryote-like 338 
enzyme demonstrated that the Cryptosporidium IMPDH is very different from its human homologs 339 
(Striepen et al., 2004; Umejiego et al., 2004). Furthermore, the “drugability” of IMPDH is well 340 
established as inhibitors of human IMPDHs have been used clinically as immunosuppressants as 341 
well as for the treatment of viral infections and cancer (Chen and Pankiewicz, 2007; Hedstrom, 342 
2009). Thus, the exclusive reliance on the salvage pathway by Cryptosporidium and its high 343 
metabolic demand for nucleotides due to the complicated lifecycle of this parasite make IMPDH a 344 
potential drug target candidate. This hypothesis is supported by the recent discovery of several 345 
Cryptosporidium IMPDH inhibitors (Umejiego et al., 2008; Maurya et al., 2009; Sharling et al., 346 
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2010; Gorla et al., 2012, 2013; Johnson et al., 2013). Another study used a yeast-two-hybrid system 347 
to identify “Phylomer®” peptides (constructed from the genomes of 25 phylogenetically diverse 348 
bacteria) that targeted the IMPDH of C. parvum and several interacting Phylomers® exhibited 349 
significant growth inhibition in vitro (Jefferies et al., 2015).  350 
 The prohibitive cost of de novo drug development, estimated to be between $500 million 351 
and $2 billion per compound successfully brought to market (Adams and Brantner, 2006), is 352 
another major limiting factor in the development of anti-cryptosporidial drugs and has resulted in 353 
drug repurposing. For example, drugs such as the human 3-hydroxy-3-methyl-glutaryl-coenzyme A 354 
(HMG-CoA) reductase inhibitor, itavastatin and Auranofin (Ridaura®) were initially approved for 355 
the treatment of rheumatoid arthritis and have been shown to be effective against Cryptosporidium 356 
in vitro (Bessoff et al., 2013; Debnath et al., 2013), which holds promise for further in vivo testing 357 
in animals and humans. 358 
 359 
7. Metabolomics 360 
Metabolomics, the study of intracellular and extracellular metabolites that are consumed and 361 
produced as a result of biological activity, is in its infancy in Cryptosporidium research but provides 362 
an avenue for biomarker discovery, drug targets and improved diagnostic techniques.  363 
Genome sequencing and biochemical data has revealed that Cryptosporidium is highly 364 
reliant on its host/environment for nutrients as it is missing key metabolic pathways and lacks the 365 
ability for de novo synthesis of nucleosides, fatty acids and amino acids (Abrahamsen et al., 2004; 366 
Xu et al., 2004). An in silico genome-scale metabolic model of C. hominis identified 540 reactions 367 
performed by 213 enzymes (Vanee et al., 2010). Of these reactions, 514 were metabolic 368 
biochemical reactions involving intracellular metabolites and 26 were transport reactions 369 
representing the movement of metabolites across the cell membrane (Vanee et al., 2010). 370 
A recent preliminary metabolomics study on Cryptosporidium developed a faecal metabolite 371 
extraction method for untargeted gas chromatography-mass spectrometry (GC-MS) analysis using 372 
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Cryptosporidium-positive and -negative human faecal samples (Ng et al., 2012). In that study, 373 
higher levels of metabolites were generally detected in Cryptosporidium-positive patients, 374 
suggesting that metabolic homeostasis and intestinal permeability were affected as a result of the 375 
infection (Ng et al., 2012). Interestingly, a more controlled metabolomics analysis of faecal 376 
metabolite profiles using experimentally infected mice reported that lower metabolite levels were 377 
generally detected in faecal samples from Cryptosporidium-infected mice (Ng-Hublin et al., 2013). 378 
Differences in metabolite profiles between different host types have been previously reported by 379 
Saric et al. (2008). In that study, a comparison of faecal metabolite profiles from mice, rats and 380 
humans showed that the levels of metabolites differed between the host species, presumably as a 381 
result of different endogenous and exogenous perturbations, and differences in the gut microbiome 382 
between species (Saric et al., 2008). Despite the differences in faecal metabolite profiles between 383 
Cryptosporidium-infected humans and mice, metabolomic analysis in both studies was still able to 384 
clearly differentiate between infected and uninfected hosts, as well as provide information on the 385 
metabolic activity of the parasite during the infection based on faecal metabolite profiles. 386 
Another study used metabolomic techniques coupled with statistical chemometric analysis 387 
of viable and irradiated Cryptosporidium oocysts and identified a number of key metabolites 388 
including aromatic and non-aromatic amino acids, carbohydrates, fatty acids and alcohol type 389 
compounds that differentiated between the viable and non-viable oocysts (Beale et al., 2013). 390 
 391 
8. Perspectives 392 
Despite the evidence that Cryptosporidium is one of four pathogens responsible for the 393 
majority of severe diarrhoea in infants and toddlers (Kotloff et al., 2013), Cryptosporidium research 394 
lags behind the other three pathogens identified (rotavirus, Shigella and enterotoxigenic Escherichia 395 
coli) (Striepen, 2013). Unlike those pathogens, no fully effective drug treatment or vaccine is 396 
available for Cryptosporidium. 397 
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Increased funding for Cryptosporidium is essential to effectively combat this disease. The 398 
US National Institutes of Health (NIH) currently spends US$4.3 million each year on 399 
Cryptosporidium research, compared with approximately $300 million on more than 600 malaria 400 
projects (Striepen, 2013). In Australia, the National Health and Medical Research Council 401 
(NHMRC) has expended ~AUD $320,000 on Cryptosporidium research projects in the last 5 years 402 
compared with more than AUD $5 million on malaria research 403 
(www.nhmrc.gov.au/grants/research-funding-statistics-and-data). It is hoped that philanthropic 404 
organizations such as the Bill and Melinda Gates Foundation, USA, (www.gatesfoundation.org), 405 
which have focused previously on monitoring rather than intervention, will fund basic research on 406 
Cryptosporidium and that more research funding will become available from various governments.  407 
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Figure legend 671 
 672 
Fig. 1. Cryptosporidium life cycle (reproduced with permission from Hijjawi et al. (2004)). 673 
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